Applied Biomedical Technology
Abstract
Guidance for Development of the Force - Applied Biomedical Technology: This program element (PE) provides applied research funding to refine concepts and ideas into potential solutions for military health and performance problems, with a view towards evaluating technical feasibility. Research in this PE is designed to address areas of interest to the Secretary of Defense regarding Wounded Warriors, capabilities identified through the Joint Capabilities Integration and Development System, and sustainment of DoD and multi-agency priority investments in science, technology, research, and development. Medical research, development, test, and evaluation priorities for the Defense Health Program (DHP) are guided by, and will support, the Quadrennial Defense Review, the National Research Action Plan for Improving Access to Mental Health Services for Veterans, Service Members, and Military Families, the National Strategy for Combating Antibiotic Resistance, and the National Strategy for Biosurveillance. Research will support efforts such as the Precision Medicine Initiative which seeks to increase the use of big data and interdisciplinary approaches to establish a fundamental understanding of military disease and injury to advance health status assessment, diagnosis, and treatment tailored to individual Service members and beneficiaries, translational research focused on protection against emerging infectious disease threats, the advancement of state of the art regenerative medicine manufacturing technologies consistent with the National Strategic Plan for Advanced Manufacturing, the advancement of global health engagement and capitalization of complementary research and technology capabilities, and the strengthening of the scientific basis for decision-making in patient safety and quality performance in the Military Health System. The program also supports the Interagency Strategic Plan for Research & Development of Blood Products and Related Technologies for Trauma Care and Emergency Preparedness. Program development and execution is peer-reviewed and coordinated with all of the Military Services, appropriate Defense agencies or activities and other federal agencies, to include the Department of Veterans Affairs, the Department of Health and Human Services, and the Department of Homeland Security. Coordination occurs through the planning and execution activities of the Joint Program Committees (JPCs), established to manage research, development, test and evaluation for DHP-sponsored research. The JPCs supported by this PE include military infectious diseases, military operational medicine, combat casualty care, radiation health effects, and clinical and rehabilitative medicine. Funds in the PE support studies and investigations leading to candidate solutions that may involve use of animal models for testing in preparation for initial human testing. As research efforts mature, the most promising efforts will transition to technology development (PE 0603115) funding. For the Army Medical Command, this PE funds the military HIV research program to refine identification methods for determining genetic diversity of the virus, to conduct preclinical work in laboratory animals including non-human primates to identify candidates for global HIV-1 vaccine, and to evaluate and prepare overseas sites for clinical trials with these vaccine candidates. For the Army Medical Command, beginning in FY 2015, funding is provided to develop strategies to prevent, mitigate, and treat antibiotic resistant bacteria in wounds through the Combating Antibiotic Resistant Bacteria - WRAIR Discovery and Wound Program. In FY 2015, Congressional Special Interest funds were provided for Restore Core Research Funding Reduction. Because of the CSI annual structure, out-year funding is not programmed. For the Air Force, this PE funds applied research which seeks to promote ‘omic’-informed personalized medicine, advanced diagnostic technologies and occupational toxicology with an emphasis on targeted prevention, diagnosis, and treatment. The delivery of pro-active, evidence-based, personalized medicine will improve health in Warfighters and beneficiaries by providing care that is specific to the situation and patient, to include preventing disease or injury, early and accurate diagnosis, and selection of appropriate and effective treatment. Personalized medicine will reduce morbidity, mortality, mission impact of illness/injury, and healthcare costs while increasing health and wellness of the AF population and efficiency of the healthcare system. This applied research supports multiple focus areas, each of which represents an identified barrier/gap which must be addressed for successful implementation of ‘omic’-informed personalized medicine. Focus areas for applied research include knowledge generation research; ethical legal and social issues/policy research; bioinformatics research; educational research; research for development of advanced genomic diagnostic system. For efforts supported by this program element, research will be pursued with the intent to support solutions that answer Air Force specific needs. During this process, the efforts of other government agencies in those areas will be assessed to avoid redundancy.
Document Details
- Document Type
- R2 Budgetary Justification
- Publication Date
- Oct 01, 2017
- Source ID
- 0602115DHA_2_0130_PB_2017
- Change Summary Explanation
- FY 2015: Realignment from Defense Health Program, Research, Development, Test and Evaluation (DHP RDT&E), Program Element (PE) 0602115-Applied Biomedical Technology (-$4.179 million) to DHP RDT&E, PE 0605502-Small Business Innovation Research (SBIR) / Small Business Technology Transfer (STTR) Program (+$4.179 million). FY 2015: Restore core research funding to the DHP RDT&E, PE 0602115-Applied Biomedical Technology (+$25.303 million). FY 2016: Restore core research funding to the DHP RDT&E, PE 0602115-Applied Biomedical Technology (+$16.904 million). FY 2017: Realignment from Defense Health Program, Research, Development, Test and Evaluation (DHP RDT&E), PE 0602115-Applied Biomedical Technology (-$8.797 million) to DHP O&M Account, Budget Activity Group (BAG) 3 - Private Sector Care (+$8.797 million). FY 2017: Realignment from Defense Health Program, Research, Development, Test and Evaluation (DHP RDT&E), PE 0602115-Applied Biomedical Technology (-$3.350 million) to DHP RDT&E PE-0603115-Medical Technology Development for Breast, Gynecological and Prostate Cancer Centers of Excellence (+$3.350 million). FY 2017: Rebalance Joint Program Committees by realigning from DHP RDTE PE 0605145-Medical Products and Support Systems Development (-0.625M) to DHP RDTE PE 0602115-Applied Biomedical Technology (+0.625M).
- Service Agency Name
- Defense Health Agency
Entities
Organizations
- Defense Health Agency
Related Documents
- Child Project: Congressional Special Interests
- Child Project: Combating Antibiotic Resistant Bacteria (CARB) - WRAIR Discovery and Wound Program (Army)
- Child Accomplishment: Combating Antibiotic Resistant Bacteria (CARB) - WRAIR Discovery and Wound Program (Army)
- Child Project: Advanced Diagnostics & Therapeutics Research & Development (AF)
- Child Accomplishment: Advanced Diagnostics & Therapeutics Research & Development (AF)
- Child Project: Core Adv Diagnostics & Epigenomics Applied Research (AF)
- Child Accomplishment: Core Adv Diagnostics & Epigenomics Applied Research (AF)
- Child Project: Core Occupational, Bioenvironmental, Aerospace Medicine & Toxicology Applied Research (AF)
- Child Accomplishment: Core Occupational, Bioenvironmental, Aerospace Medicine & Toxicology Applied Research (AF)
- Child Project: GDF Applied Biomedical Technology
- Child Accomplishment: GDF Applied Biomedical Technology
- Child Project: Military HIV Research Program (Army)
- Child Accomplishment: Military HIV Research Program